Introduction
Alterations in the function of the wild-type p53 (WTp53) protein are commonly observed among human cancers and may impact on human tumor diagnosis, prognosis, and response to cancer therapy. In somatic cells, genotoxic agents are known to activate and stabilize the p53 protein through initial sensing of ionizing radiation (IR) or ultraviolet (UV) damage by the ATM or ATR kinases, respectively. The p53 protein is stabilized through a series of post-translational phosphorylations, dephosphorylations, and acetylations at its amino-and carboxy-termini (Melchior and Hengst, 2002; Sharpless and DePinho, 2002) . This stabilization leads to transcriptional activation of downstream effector genes (i.e. Bax, p21 WAF , Mdm2, Gadd45, 14-3-3s) resulting in cell cycle checkpoint activation, apoptosis, or terminal growth arrest dependent on tissue type, stressor, and level of damage (Lin and Benchimol, 1995; Wahl and Carr, 2001; Gangopadhyay et al., 2002) .
In mutant p53 (MTp53)-expressing cells, cellular carcinogenesis can occur secondary to the loss of WTp53 function because of coexpressed transdominant MTp53 proteins or to a WTp53-independent, gain of function for selected MTp53 proteins (Dittmer et al., 1993; Sigal and Rotter, 2000; van Oijen and Slootweg, 2000; Cadwell and Zambetti, 2001) . Data derived from both MTp53-expressing human and murine fibroblasts support the gain of function model as an important mechanism for carcinogenesis (Gualberto et al., 1998) . These studies have suggested that different p53 gain of function mutant classes (i.e. DNA contact mutants or conformational mutants) may have disparate cell transformation abilities (Gualberto et al., 1998) . MTp53 gain of function mutants can transactivate a number of genes important in tumor cell survival including MDR-1, myc, PCNA, HSP-70, and other members of the p53 family including p63 and p73 (Gaiddon et al., 2001; Monti et al., 2002; Strano et al., 2002) . This altered gene expression may give rise to cell clones that have: variable mutation frequencies; sensitivities to DNA-damaging agents or DNA repair; tumorigenicity and metastasis; and mitotic control (Hsiao et al., 1994; Kieser et al., 1994; Iwamoto et al., 1996; Grant et al., 1998; Liu et al., 2000; Sigal and Rotter, 2000; Iwanaga and Jeang, 2002; Morris, 2002) . Whether the acquisition of these aggressive cell phenotypes is inter-related is not well studied.
In this context, the unsuccessful treatment of human tumors by radiotherapy and chemotherapy leads to the regrowth of clonogenic cells that heralds local treatment failure and/or metastastic spread. We have previously observed that relative resistance can be acquired in rat embryo fibroblasts (REF cells) and human neuroblastoma cells following transfection with a highly transforming, missense, core-DNA binding mutant p53 allele (i.e. MTp53pro193) that abrogates the G1 checkpoint (Slingerland et al., 1993; Bristow et al., 1998; Gangopadhyay et al., 2002) . The acquired radioresistance was hypothesized to occur by transdominance of the MTp53pro193 protein, yet the possibility also remained that MTp53pro193 proteins have gain of function in mediating the resistant phenotype. In this study, we report that p53 À/À MEF cells exhibit clonal heterogeneity in their sensitivity to the DNA-damaging agents cisplatinum (cDDP), methotrexate (MTX), and UV or IR radiation, independent of ras transformation. We also report that ras-transformed p53 À/À MEF transformants, which express an exogenous MTp53pro193 allele, acquire radio-and chemoresistance (but not altered tumor growth or experimental metastatic capacity) because of gain of MTp53 function. À/À MEF transformants transfected with an activated ras allele (i.e. clones T63-R1, T63-R2, and T63-R3). Individual data points are the mean survival from three to six, independent experiments. The values for surviving fraction after 2 Gy (SF2) and the dose required to reduce surviving fraction to 10% (i.e. D 10 ) as previously described (Bristow et al., 1998) À/À (T63-POP) MEF populations. For clonogenic survival assays, cells were treated 16-18 h after seeding with graded doses of ionizing radiation (i.e. 0-10 Gy) delivered using 137 Cs g-rays under aerobic conditions and at room temperature. UV irradiation of cells covered in a layer of PBS was performed as previously described using a germicidal lamp (254 nm flux) at a dose rate of 8 J/m 2 per minute. Treatment with cis-platinum was for 72 h at varying concentrations with drug mixed in 10% FCS/a-MEM. Surviving colonies were fixed and stained 8-10 days post-treatment with 5-7 in culture. Survival was expressed as the relative plating efficiencies of the irradiated to control cells. For each transfectant clone, two to six survival curves were obtained (average of three experiments per cell line). T63-R clones were derived by calcium-phosphate-mediated transfection as previously described (Peacock et al., 1995) using 10 mg NIH3T3 carrier DNA in addition to 2 mg pEJras-neo. Clonal selection in a-MEM containing gentamycin-G418 commenced 48 h following transfection and foci isolated with cloning cylinders before freezing in liquid nitrogen. Clones were characterized at passage 5-7 in culture MTp53 gain of function phenotypes in MEF transformants RG Bristow et al Our initial experiments used primary p53 +/+ and p53 À/À MEF homozygote populations that were originally derived from crossing MEF (p53 +/À ) heterozygote mice of mixed C57BL/6 and 129/Sv genetic background, and these were kindly provided by Donehower et al (1992) . We observed resistance to IR, UV, cDDP, and MTX (data not shown) as shown in Figure 1 in pooled populations of p53 À/À MEFs (T63-POP) relative to p53 +/+ MEFs (T40-POP), consistent with previous studies (reviewed by Bristow et al., 1996) . Differences in cis-platinum and UV-radiation survival between untransfected PT40-POP and PT63-POP cell lines were significant based on calculated IC 50 and/or D 10 values (P-values ranging from 0.01 to 0.05). Increased resistance to MTX for the p53 À/À MEF population was also observed (data not shown). To test for the additional effect of cell transformation on DNA damage responses, the IR sensitivity of similar p53
MEF clones transformed with an activated ras allele was determined (i.e. pEJ-ras). Post-transfection, the relative IR survival in these transformants was not augmented beyond that observed for the PT63-POP population, suggesting that ras transformation does not further increase resistance to DNA damage under these conditions (Figure 1) .
During these studies, we observed that one (i.e. T63-R2) out of the three clones tested exhibited relative IR sensitivity, with SF2 and D 10 values similar to those of the p53 +/+ T40-POP MEF population. This suggested that clonal heterogeneity in DNA damage responses might exist pretransfection within the p53 À/À PT63-POP cell population, and we therefore subcloned the p53 À/À T63-POP MEF population using limiting dilution at passage 2 in culture. The SF2Gy (i.e. survival in the lowdose region of the curve and representing sublethal damage repair) and D 10 (i.e. survival in the higher-dose region of the survival curve) values for 10 subclones of the PT63-POP population (each denoted T63-N1 through T63-N10) are shown in Figure 2 . These p53 À/À subclones exhibited differences in radiosensitivity based on relative SF2 (ranging from 0.6 to 0.9) and D 10 (range of 5.4-8.2 Gy) values; when these individual values were meaned, the final value closely approximated the original SF2 and D 10 values for the pooled PT63-POP MEF pool. This observation suggests that secondary genetic changes following subcloning (rather than solely a lack of WTp53 expression) may give rise to the disparate cellular sensitivity to DNA-damaging agents published for p53 À/À MEF cells (Bristow et al., 1996; Powell et al., 1995; Slichenmyer et al., 1993) . In this scenario, the most resistant existing clones in a population will dominate the phenotype of a pooled p53 À/À MEF population, at the time of assay.
Consequently, we tested whether radioresistance could be associated with a gain of MTp53 protein function by transfecting the highly transforming, murine missense MTp53pro193 allele (carrying a hygromycinresistance marker) into the ras-transformed T63-R2 MEF (p53 À/À ) clone. This particular MTp53 allele was chosen as it had been associated with acquired radioresistance when it was expressed at high levels in all our previous studies utilizing rodent and human transfectants (Bristow et al., 1998; Gangopadhyay et al., 2002) . The T63-R2 clone was chosen as it was relatively sensitive among the T63-ras clones and any increased radioresistance could be readily observed and tested (unlike the T63-R1 and T63-R3 clones, which were already highly resistant, presumably because of secondary genetic events).
Following transfection of the parent T63-R2 transformant, we further derived two hygromycin-resistant p53 À/À MEF transformant subclones (i.e. T63-R2-GF8 and T63-R2-GF12), which did not express the exogenous MTp53pro193 allele. These two subclones served as transfection controls in future assays. Three other hygromycin-resistant p53 À/À MEF transformants (i.e. the T63-R2-GF2, T63-R2-GF4, and T63-R2-GF14 subclones) expressed the MTp53pro193 allele, which MEFs confirmed that all clones were of mesenchymal and fibroblast lineage. Consistent with previous reports, we were unable to clone the pooled population of p53 +/+ MEFs (Harvey et al., 1993) MTp53 gain of function phenotypes in MEF transformants RG Bristow et al was confirmed using immunoprecipitation of p53 with control (PAb419), pan-p53 (PAb421), and mutant p53-specific (PAb240) antibodies. We did not observe any differences in morphology in vitro or IR-induced apoptosis (i.e. less than 3% at doses up to 20 Gy for any clone) among the entire panel of T63-R2-derived subclones (data not shown). When tested for survival following ionizing radiation, the MTp53pro193-expressing p53 À/À MEF transfectant subclones had acquired relative radioresistance based on both SF2 and D 10 values when compared to the transfection control and the parental transfectants (P ¼ 0.03). Of note, the levels of MTp53 protein expression were highest for the T63-GF14 clone, which had the highest SF2 value. The sensitivity of the individual MTp53-expressing p53 À/À MEF subclones to UV radiation and cis-platinum was more variable, but significant resistance was observed for these cell lines based on the relative UV radiation D 50 (P ¼ 0.008) and cis-platinum ICD 50 (P ¼ 0.05) values (representing survival in the repair-associated, low-dose region of these survival curves). Using the SF2 values alone as a translational example to the clinic, the increase of SF2 from 0.5 to 0.8 would decrease the final survival after 35 radiation treatments by 4-5 logs of cell kill.
In order to confirm the ability of this specific MTp53pro193 allele to confer radioresistance, we also determined the clonogenic survival of a population of p53 À/À DP16 murine erythroleukemia cells that either express or do not express exogenous MTp53pro193 allele (Lin and Benchimol, 1995) . In this model, the DP16 cells that expressed the proline 193 missense mutant were observed to have a significantly higher SF2 value (0.8670.1) than the parental null-p53 DP16 cell line (0.6570.1; Po0.05). Similar differences were noted for D 10 values (Po0.05). Again, no differences in radiation-induced apoptosis were observed between these two cell lines at 24 h following 2 and 10 Gy (data not shown).
Given the gain of function observed for the MTp53pro193 allele, we wished to see whether the expression of this allele additionally led to aggressive phenotypes of increased local tumor growth and metastatic potential (based on an experimental metastatic assay) in vivo within the MEF T63-ras-transformant clones. Similar to data presented above, clonal heterogeneity was observed for both in vivo end points (see Td and EME values in Table 1 ). There was no evidence for MTp53pro193 gain of function in mediating decreased tumor doubling times or increased experimental metastatic ability in the T63-R2-GF2/ GF4/GF14 series of MTp53-expressing subclones when compared to transfection control subclones (T63-R2-GF8/GF12) or the parent (T63-R2) or other (T63-R1/ R3) transformant clones, P>0.05 (Table 1) . These results suggest that phenotypes associated with local resistance to cancer therapy can be discordant from ras protein expressed in the various cell lines were measured by either Western immunoblot or immunoprecipitation analyses (Peacock et al., 1995) . Tumor growth for each MEF cell line was assessed following injection of 1-5 Â 10 5 cells (prepassage 7 in culture) intramuscularly into the hind legs of 2-5 SCID mice (Ontario Cancer Institute stock). Tumor doubling time in vivo was calculated as the time taken for tumors to increase from 0.5 to 1.0 g in weight. Additionally, the time required for tumors to grow to a size of 0.5 g from the time of injection was calculated using serial measurements of tumor diameter. None of the clones presented in Table 1 had the ability for spontaneous metastasis to the lungs, liver, or lymph nodes at necropsy. Experimental metastatic efficiency was therefore determined by injecting either 5 Â 10 4 or 1 Â 10 5 cells intravenously (lateral tail vein) into groups of seven SCID mice. At the time of injection, cells were also plated on plastic to determine the untreated plating efficiency for each cell suspension. Mice were killed 3 weeks later and their lungs removed, fixed in Bouin's solution, and the number of microscopic nodules present within each set of lungs was determined with the aid of a dissecting microscope. The metastatic efficiency was calculated as the number of lung nodules per clonogenic cell injected Our results add to the literature regarding other MTp53 alleles which exhibit gain of function properties. Rotter and colleagues have shown decreased radiation and chemotherapy-induced apoptosis in p53 À/À murine leukemic cells which expressed a temperature-sensitive murine MTp53vall35 protein (valine to alanine 135) when cells were incubated at the permissive temperature for mutant p53 conformation (Li et al., 1998) . Similarly, Blandino (1999) found that expression of the MTp53his275 mutant protein (but not MTp53his273) when expressed in p53 À/À HT1299 cells increased the resistance to etoposide and lower doses of cis-platinum similar to our observation of the T63-GF subclones. It is not known whether the resistant phenotypes documented in the two latter studies were related to increased tumorigenicity or metastatic ability. Apoptosis following DNA damage exposure does not account for our observations of increased clonogenic cell survival among the MTp53pro193-expressing transformant subclones and was nonpredictive of the longer-term clonogenic death, which may occur secondary to tumor cell senescence or necrosis (Chang et al., 1999; Illidge et al., 2000; Tannock and Lee, 2001) .
It may be that the MTp53pro193 protein has other gain of function properties more related to DNA repair occurring during DNA damage. For example, resistance to ionizing radiation in MTp53pro193-expressing cells may be mediated by increased DNA double-strand break rejoining or base excision repair. Similarly, repair of cis-platinum and UV irradiation would be mediated through altered nucleotide excision repair or DNA lesion bypass (Hoeijmakers, 2001; Gangopadhyay et al., 2002) . Indeed, the expression of the MTp53pro193 protein consistently altered survival in the DNA repairassociated, low-dose shoulder region of the clonogenic survival curves in Figure 3 , and the p53 protein has been implicated in a number of DNA repair pathways (Albor et al., 1998; Tang et al., 1999; Offer et al., 2001; Wiesmuller, 2001; Bernstein et al., 2002; Smith and Seo, 2002) . Future studies utilizing gain of function MTp53 proteins in isogenic systems that can be differentially expressed before, during and after DNA damage may clarify the direct, or indirect, nature of the MTp53 proteins' effect on DNA repair and other mechanisms that may alter cell survival following DNA damage.
There have been a number of clinical pathologic reviews that have suggested that alterations in p53 function, including p53 gain of function, may lead to increased radioresistance and chemoresistance among epithelial tumors in patients who are receiving radical radiotherapy (Bristow et al., 1996; Kirsch and Kastan, 1998; Soussi and Beroud, 2001; van Oijen and Slootweg, 2000) . Specific assays may be required to determine gain of p53 function mutant protein effects in pretreatment biopsies to allow for MTp53-targeted strategies to be designed to combat this clinically resistant scenario (Bullock et al., 2000; Roth et al., 2001; Selivanova, 2001; Foster et al., 1999; Liu and Gelmann, 2002; Pugacheva et al., 2002; Takimoto et al., 2002) . These strategies will be useful adjuncts to current chemotherapy or radiotherapy regimens in improving local tumor control for MTp53-expressing tumors. . T63-R-GF subclones were derived by a second calcium-phosphate-mediated-transfection (Peacock et al., 1995) using 20 mg of MTp53pro193 (entire mouse p53 genes cloned into pUC18 with point mutations at codon 193 (arginine to proline)) and pHMR272 (hygromycin resistance gene). Clonal selection in a-MEM containing 15 mg/ml hygromycin commenced 48 h following transfection and foci isolated with cloning cylinders before freezing in liquid nitrogen
